IHS Chemical Week

Bayer to acquire birth control firm Conceptus for $1.1 billion

11:48 AM MDT | April 29, 2013

Bayer HealthCare has signed a merger agreement with Conceptus (Mountain View; CA), the developer of the Essure procedure—a leading nonsurgical, permanent birth-control method, Bayer announced today. Bayer, following the acquisition, will be able to offer a complete range of short-term, long-term, and permanent contraceptive choices for women, the company says. Bayer will launch a public tender offer to acquire all shares in Conceptus within the next 10 business days in a transaction valuing Conceptus at approximately $1.1 billion, representing $31.00/share in...

Access is for Chemweek 24/7 PLUS Members ONLY

This information is only available to Chemweek 24/7 PLUS members who have subscribed to Chemweek’s Business Daily. If you are a member, please log in, OR if you have a trial membership, please use your trial membership account information. 


Forgot your user ID or password? Click here to have it sent to you.



If you are not yet a subscriber and would like to access the turnkey information found only in Chemweek’s Business Daily, subscribe now and you’ll get the most important news of the chemical industry delivered directly to your inbox—every day.

Sign up for a FREE 15-day trial of IHS Chemical Week Business Daily

contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa